Abstract
Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and/or spread, or treating a CMV infection, is also described.
| Original language | English (US) |
|---|---|
| U.S. patent number | 12570720 |
| Filing date | 9/15/20 |
| State | Published - Mar 10 2026 |
Fingerprint
Dive into the research topics of 'Engineered receptors for human cytomegalovirus and uses thereof'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS